Caribou Biosciences, Inc
2929 7th Street
Suite 150
Berkeley
California
94710
United States
Tel: 510-982-6030
61 articles with Caribou Biosciences, Inc
-
BioSpace Movers & Shakers, Jan. 21
1/21/2022
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. -
BioSpace Movers & Shakers, Nov. 12
11/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
-
DA32 Life Science SPAC Prices $200M IPO
7/28/2021
Deerfield Management and ARCH Venture Partners have partnered with venture capital firm Section 32 to sponsor DA32 Life Science Tech Acquisition Corp, a blank check company that is today priced for $200 million in an initial public offering (IPO). -
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
7/27/2021
Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share.
-
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
7/23/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share.
-
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
7/12/2021
Caribou Biosciences, Inc. announced today that the first patient has been dosed in its open-label, multicenter ANTLER phase 1 clinical trial ( NCT04637763 ) to evaluate the company’s lead product candidate, CB-010.
-
Money on the Move: June 30 – July 6
7/7/2021
The long weekend didn't slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. -
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors
6/22/2021
Caribou Biosciences, Inc. announced today that it has appointed Scott Braunstein, M.D. to its board of directors.
-
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson's disease and other neurodegenerative conditions.
-
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board
5/17/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has expanded its scientific advisory board (SAB) with the appointment of two new members: Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center; and Christopher Sturgeon, Ph.D.,
-
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors
5/5/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Andrew Guggenhime to its board of directors. Mr. Guggenhime is an accomplished biopharmaceutical industry leader with more than 20 years of experience.
-
The company’s overarching aim is to edit and equip cells with molecular tools, through CRISPR, to eliminate certain cancers.
-
Money on the Move – March 3-9
3/10/2021
Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week. -
Caribou Biosciences to Participate in Three Upcoming Investor Conferences in March
3/8/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that Rachel Haurwitz, Ph.D., Caribou’s President and Chief Executive Officer, will present a company overview at upcoming investor conferences in March. Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 1:15 p.m. ET
-
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline
3/3/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing. Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
-
Caribou co-founder and CRISPR pioneer Jennifer Doudna said the company has leveraged its gene-editing technology platform to create a “promising clinical-stage therapeutic and a pipeline of pre-clinical allogeneic CAR-T and CAR-NK cell therapies that are potentially transformative for patients wi...
-
BioSpace Movers & Shakers, Feb. 12
2/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
2/10/2021
AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.
-
AbbVie committed up to another $300 in potential milestone payments.